Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response And Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)

被引：0
|
作者：
Elewski, B.
Lebwohl, M.
Papp, K.
Nakagawa, H.
Sigurgeirsson, B.
Tsai, T.
Tyring, S.
Hampele, I.
Karpov, A.
Helou, S.
Papavassilis, C.
机构：
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response and Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
    Elewski, B.
    Lebwohl, M.
    Papp, K.
    Nakagawa, H.
    Sigurgeirsson, B.
    Tsai, T. -F.
    Tyring, S.
    Hampele, I.
    Karpov, A.
    Helou, S.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 43 - 43
  • [2] Efficacy and safety of secukinumab in moderate to severe plaque psoriasis
    Aparicio Rubio, Celia
    Monteagudo Santolaya, Emilio
    Cornejo Uixeda, Silvia
    Prieto Castello, Manuel
    Antonino de la Camara, Gonzalo
    Quintana Vergara, Belen
    Sanchez Alcaraz, Agustin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 299 - 299
  • [3] Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: A subanalysis of the ERASURE study
    Blauvelt, Andrew
    Gottlieb, Alice
    Sigurgeirsson, Bardur
    Papavassilis, Charis
    Martin, Ruvie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB2 - AB2
  • [4] Secukinumab in moderate-to-severe plaque psoriasis: Results from the Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)
    Thaci, D.
    Humeniuk, J.
    Frambach, Y.
    Bissonnette, R.
    Goodman, J.
    Shevadeb, S.
    Gong, Y.
    Helou, S.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 13 - 13
  • [5] Secukinumab shows sustained response in subjects with moderate-to-severe plaque psoriasis: a subanalysis of the ERASURE phase 3 study
    Wylie, A.
    Lebwohl, M.
    Vender, R.
    Menter, A.
    Karpov, A.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 83 - 83
  • [6] Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
    Reich, Kristian
    Puig, Lluis
    Szepietowski, Jacek C.
    Paul, Carle
    Lacour, Jean Philippe
    Tsianakas, Athanasios
    Sieder, Christian
    Rissler, Michael
    Jagiello, Piotr
    Orsenigo, Roberto
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90
  • [7] Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)
    Blauvelt, Andrew
    Gottlieb, Alice
    Prinz, Jorg
    Pathan, Rashidkhan
    Cooper, Simon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB185 - AB185
  • [8] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [9] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [10] Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study
    Wu, Nan-Lin
    Hsu, Chih-Jung
    Sun, Fang-Ju
    Tsai, Tsen-Fang
    JOURNAL OF DERMATOLOGY, 2017, 44 (10): : 1129 - 1137
12345